|
NANOVIRICIDES, INC.
NYSE SYMBOL: NNVC
Last Price: 1.91 | Website | Latest News
Good Morning Ggg,
In case you did not read last night's full alert on NNVC for today - make sure you do so RIGHT NOW and put it on your screen immediately!
The news is palpable and Wall Street is getting on board head first...
BIOTECH IS BACK!
Emerging from a 4 year slump, BioTech ETF's are up 25% this year, beating the S&P 500 by 9 percentage points, with no signs of slowing down.
Tomorrow's New Alert is riding the BioTech wave and could be the next small-cap rocket everyone’s sleeping on.
This isn’t just another “COVID penny stock” — this company built a broad-spectrum antiviral platform designed to neutralize entire classes of viruses. If that tech delivers… we’re talking massive scalability.
Not to mention it's float is tight, volume is picking up, and we have a chart in the midst of TOTAL BREAKOUT!
WE ARE ISSUING AN IMMEDIATE ALERT ON NNVC FOR TODAY!
NanoViricides, Inc. (NYSE: NNVC) is a clinical-stage nano-biopharmaceutical company pioneering an antiviral platform called “nanoviricides.” Their technology is host-mimetic: it mimics the cell surface receptors that viruses bind to, then attacks and dismantles the virus particles directly.
Their lead drug candidate, NV-387, is designed as a broad-spectrum antiviral (targeting RSV, influenza, coronavirus, orthopoxviruses) and has already cleared Phase I testing with no reported adverse events. NNVC's other advanced drug candidate is NV-HHV-1 - a topical for the treatment of Shingles.
The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.
Most recently, NNVC announced it's NV-387 drug showed strong activity against Measles while also protecting the lungs. There is currently no approved drug for measles.
The business model: build a platform that can tackle many viral diseases (not just one “hot” virus), license out or commercialize downstream candidates, and scale if one hits. As they state: “discover, develop and commercialize therapeutics to advance the care of patients suffering from life-threatening viral infections.”
Pretty cool right? So it's no wonder the Street has been latching on to this Biotech hidden gem as of late...
NNVC IN THE MIDST OF TOTAL BREAKOUT!
There's no doubt NNVC has been on a roll the last few weeks and it appears to only be getting started...
Crushing all resistance and printing new 1 Year Highs, we now have to look at NNVC's 2 year high of 3.59 as our next level to break - 88% HIGHER than the current price!
What's most important here is our RSI Momentum indicator. Even while NNVC has gone, for all purposes...PARABOLIC, RSI remains in the "POWER ZONE" and NOT Overbought - hinting at more room to GO!
And the analysts agree...
Barchart currently rates NNVC an 88% BUY with Strong Strength and STRONGEST Direction!
CNN currently gives NNVC a "BUY" Rating with a $6.50 Price Forecast!
That's a 240% GAIN from here!!
StockAnalysis.com notes a STRONG BUY Rating by the analysts at EF Hutton.
In addition, both StockInvest and TipRanks have NNVC as "STRONG BUY" Candidates.
THE BOTTOM LINE
With the immense potential of the company's nanoviricides platform across so many virus and illnesses + the fact that their lead drug candidate, NV-387, has already cleared FDA Phase 1 testing, the future is looking bright for NNVC.
THIS TOTAL BREAKOUT RALLY MAY JUST BE GETTING STARTED!
With multiple analysts on board and immense upside, NNVC may be the one BioTech play you must not miss!
Make sure you put it on your screen RIGHT NOW and
Follow on Twitter for Updates + Play-by-Play!
|
